Imatinib therapy reduces radiation-induced pulmonary mast cell influx and delays lung disease in the mouse

Abstract

Purpose: Radiotherapy can induce the inflammatory response of alveolitis and the excessive repair response of fibrosis through incompletely defined mechanisms. In previous murine studies we showed the alveolitis response to thoracic irradiation to correlate with pulmonary mast cell numbers and fibrosis severity to partially depend on the extent of alveolitis. Herein we investigate whether the mast cell blocker imatinib reduces the alveolitis and/or fibrosis response to irradiation.

Material and methods: Mice of three strains received 18 Gy whole thorax irradiation and a subset of these were treated with imatinib (100 mg/kg) daily from the day of irradiation until euthanasia due to the presentation of distress symptoms.

Results: Imatinib treatment increased the post irradiation survival time of the mice by an average of 23% and significantly reduced the pulmonary mast cell influx. The alveolitis and fibrosis phenotypes, evident histologically, were not altered by imatinib treatment in mice euthanised upon presentation of respiratory distress. The imatinib treated mice did, however, have less disease than did mice receiving radiation alone, when both groups were assessed at a common time point.

Conclusions: We conclude that imatinib treatment reduces radiation-induced mast cell influx into the lungs and delays the alveolitis or fibrosis response of mice.

Keywords:

• imatinib
• lung
• mast cell
• alveolitis
• radiation
• murine models

Acknowledgements

This work was supported by funding from the Canadian Cancer Society (grant #19182) and Fonds de la Recherche en Santé Québec.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.